JP6186434B2 - 窒素複素環誘導体及びその医薬品への応用 - Google Patents

窒素複素環誘導体及びその医薬品への応用 Download PDF

Info

Publication number
JP6186434B2
JP6186434B2 JP2015521942A JP2015521942A JP6186434B2 JP 6186434 B2 JP6186434 B2 JP 6186434B2 JP 2015521942 A JP2015521942 A JP 2015521942A JP 2015521942 A JP2015521942 A JP 2015521942A JP 6186434 B2 JP6186434 B2 JP 6186434B2
Authority
JP
Japan
Prior art keywords
alkoxy
aliphatic
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526411A5 (enExample
JP2015526411A (ja
Inventor
ジャン、インジュン
ジャン、ジエンツン
ワン、シャオジュン
リン、ルンフェン
ツァオ、シェンティエン
ワン、ジャオヘ
リ、ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2015526411A publication Critical patent/JP2015526411A/ja
Publication of JP2015526411A5 publication Critical patent/JP2015526411A5/ja
Application granted granted Critical
Publication of JP6186434B2 publication Critical patent/JP6186434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015521942A 2012-07-18 2013-07-18 窒素複素環誘導体及びその医薬品への応用 Active JP6186434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210250660.6 2012-07-18
CN201210250660 2012-07-18
PCT/CN2013/000860 WO2014012360A1 (en) 2012-07-18 2013-07-18 Nitrogenous heterocyclic derivatives and their application in drugs

Publications (3)

Publication Number Publication Date
JP2015526411A JP2015526411A (ja) 2015-09-10
JP2015526411A5 JP2015526411A5 (enExample) 2016-09-01
JP6186434B2 true JP6186434B2 (ja) 2017-08-23

Family

ID=49948222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521942A Active JP6186434B2 (ja) 2012-07-18 2013-07-18 窒素複素環誘導体及びその医薬品への応用

Country Status (12)

Country Link
US (1) US9434695B2 (enExample)
EP (1) EP2875001B1 (enExample)
JP (1) JP6186434B2 (enExample)
KR (1) KR102057877B1 (enExample)
CN (1) CN103570630B (enExample)
AU (1) AU2013292950C1 (enExample)
BR (1) BR112014030284B1 (enExample)
CA (1) CA2872110C (enExample)
ES (1) ES2716008T3 (enExample)
MX (1) MX2015000830A (enExample)
RU (1) RU2701156C9 (enExample)
WO (1) WO2014012360A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
CN106397408B (zh) * 2015-07-30 2019-04-02 四川大学 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106083817B (zh) * 2016-06-14 2019-01-18 四川大学 吡非尼酮衍生物及其制备方法
CN106045971B (zh) * 2016-06-16 2018-12-21 杨若一 吡非尼酮衍生物及其制备方法
CN107663177B (zh) * 2016-07-27 2022-07-08 广东东阳光药业有限公司 2,6-二甲基嘧啶酮衍生物的盐及其用途
WO2018019244A1 (zh) * 2016-07-27 2018-02-01 广东东阳光药业有限公司 2,6-二甲基嘧啶酮衍生物的盐及其用途
EP3652158B1 (en) * 2017-07-14 2024-05-29 Sunshine Lake Pharma Co., Ltd. Method for preparing pyrimidone compound
CN112770757B (zh) * 2018-10-19 2024-01-16 广东东阳光药业股份有限公司 一种治疗纤维化疾病的药物组合或药物组合物
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN109734618B (zh) * 2019-02-27 2021-08-17 宜春学院 一种苯氧乙酰胺类化合物的制备方法和苯氧乙酰胺类化合物
CN109942497A (zh) * 2019-05-06 2019-06-28 南京工业大学 一种多取代嘧啶酮化合物及其制备方法
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
IL307258A (en) 2021-04-05 2023-11-01 Halia Therapeutics Inc NEK7 inhibitors
US20250177382A1 (en) 2021-04-22 2025-06-05 Halia Therapeutics, Inc. Nek7 inhibitors
WO2023056935A1 (zh) 2021-10-09 2023-04-13 广东东阳光药业有限公司 抗纤维化组合物
KR102762725B1 (ko) * 2022-03-24 2025-02-06 주식회사 케이에스비튜젠 레보드로프로피진을 유효성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185689A (en) 1965-05-25 Tolyl-x-(jh)-pyrimidones
DE2808193A1 (de) 1978-02-25 1979-09-06 Basf Ag Pyridazon-verbindungen
DE3202678A1 (de) 1982-01-28 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte 4,5-dimethoxy-pyridazone, verfahren zu ihrer herstellung, diese enthaltende herbizide und ihre anwendung als herbizide
US5149810A (en) 1988-04-22 1992-09-22 Imperial Chemical Industries Plc Pyrimidine compounds
GB8818560D0 (en) 1988-08-04 1988-09-07 Ici Plc Novel compounds
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
GB8908638D0 (en) 1989-04-17 1989-06-01 Ici Plc Novel compounds
GB8915962D0 (en) 1989-07-12 1989-08-31 Ici Plc Novel compounds
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
GB9022445D0 (en) 1990-10-16 1990-11-28 Ici Plc Heterocyclic compounds
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
TW229142B (enExample) 1992-04-15 1994-09-01 Nissan Detrochem Corp
CA2094949A1 (en) 1992-04-28 1993-10-29 Eiki Nagano Pyrimidone derivatives and their use
EP0724573A1 (en) 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
DE4431218A1 (de) 1994-09-02 1996-03-07 Bayer Ag Substituierte Pyrimidin(thi)one
DE4432888A1 (de) 1994-09-15 1996-03-21 Bayer Ag Verwendung von Aryluracilen im semi- und nicht-selektiven Bereich der Unkrautbekämpfung
KR100300566B1 (ko) 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
DE19520613A1 (de) 1995-06-06 1996-12-12 Bayer Ag Phenylpyridazinone
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1305466A (zh) 1998-04-09 2001-07-25 拜尔公司 取代的苯基哒嗪酮类化合物
NZ522773A (en) * 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
WO2002053156A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ii b
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
EP1470112A1 (en) 2002-01-18 2004-10-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
SI1490064T1 (sl) 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
CA2558272C (en) 2004-03-05 2011-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
CA2565437A1 (en) * 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN1308028C (zh) 2004-09-10 2007-04-04 石药集团中奇制药技术（石家庄）有限公司 一种治疗肝纤维化的药物及其制备方法
US20070270446A1 (en) 2004-10-06 2007-11-22 Smithkline Beecham Corporation Reversed Pyrimidinone Compounds as Calcilytics
MX2007004514A (es) * 2004-10-13 2007-05-09 Pharmacia & Upjohn Co Llc Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6 oxopirimidin-1(6h)-il]-n-(2-hidroxetil)-4-metilbenzamida.
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
KR20080080136A (ko) 2005-11-22 2008-09-02 스미스클라인 비참 코포레이션 칼실리틱 화합물
US20070129379A1 (en) 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
PE20080150A1 (es) 2006-06-02 2008-04-11 Janssen Pharmaceutica Nv Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
WO2007142217A1 (ja) 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
EP2079724B1 (en) * 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
BRPI0716579A2 (pt) 2006-08-25 2013-10-08 Boehringer Ingelheim Int Derivados de piridona com atividade antagonista ao mch e medicamentos que compreendem estes compostos
WO2008041090A1 (en) 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
WO2008086226A2 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US8198276B2 (en) 2007-06-06 2012-06-12 Xcovery Holding Company Llc Kinase inhibitor compounds
WO2008156607A1 (en) 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
BRPI0813244B8 (pt) 2007-06-27 2021-05-25 Astrazeneca Ab compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EP2188288A1 (en) * 2007-09-11 2010-05-26 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
US8329711B2 (en) 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
CN101235013A (zh) * 2008-03-10 2008-08-06 广东东阳光药业有限公司 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20100190731A1 (en) * 2009-01-26 2010-07-29 Jeff Olgin Methods for treating acute myocardial infarctions and associated disorders
US9006454B2 (en) 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
JP5722883B2 (ja) 2009-05-25 2015-05-27 中南大学Ｃｅｎｔｒａｌ Ｓｏｕｔｈ Ｕｎｉｖｅｒｓｉｔｙ １−（置換ベンジル）−５−トリフルオロメチル−２−（１ｈ）ピリドン化合物及びその塩、並びにその製造方法及びその用途
JP5583758B2 (ja) 2009-05-25 2014-09-03 中南大学 １−（置換アリール）−５−トリフルオロメチル−２−（１ｈ）ピリドン化合物及びその塩、並びにその製造方法及びその用途
CN101921225B (zh) 2009-06-11 2013-04-03 北京凯得尔森生物技术有限公司 吡啡尼酮类化合物、其制备方法和应用
PL2542084T3 (pl) 2010-03-04 2018-05-30 Merck Sharp & Dohme Corp. Inhibitory katecholo-O-metylotransferazy i ich zastosowanie w leczeniu zaburzeń psychotycznych
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
JP2014515345A (ja) * 2011-01-10 2014-06-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのピリミジノン誘導体
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
US8859559B2 (en) * 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease

Also Published As

Publication number Publication date
EP2875001A4 (en) 2016-06-01
CA2872110A1 (en) 2014-01-23
EP2875001A1 (en) 2015-05-27
RU2701156C9 (ru) 2019-12-18
AU2013292950B2 (en) 2015-09-10
WO2014012360A1 (en) 2014-01-23
KR20150036223A (ko) 2015-04-07
BR112014030284A2 (pt) 2017-06-27
EP2875001B1 (en) 2019-01-09
RU2015105262A (ru) 2016-09-10
KR102057877B1 (ko) 2019-12-20
AU2013292950A1 (en) 2014-11-13
CN103570630B (zh) 2016-04-20
HK1207065A1 (en) 2016-01-22
MX2015000830A (es) 2015-10-26
RU2701156C2 (ru) 2019-09-25
CA2872110C (en) 2019-08-06
CN103570630A (zh) 2014-02-12
BR112014030284B1 (pt) 2021-11-30
US20150087639A1 (en) 2015-03-26
US9434695B2 (en) 2016-09-06
AU2013292950C1 (en) 2016-01-21
JP2015526411A (ja) 2015-09-10
ES2716008T3 (es) 2019-06-07

Similar Documents

Publication Publication Date Title
JP6186434B2 (ja) 窒素複素環誘導体及びその医薬品への応用
US11566001B2 (en) Hepatitis B capsid assembly modulators
RU2694254C1 (ru) Азотсодержащие гетероциклические производные и их применение в лекарственных препаратах
CA2985542A1 (en) Triazole agonists of the apj receptor
AU2022334480A1 (en) Spiro indoline inhibitors of kif18a
KR102731925B1 (ko) 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
CA2897469A1 (en) Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
CN102858769A (zh) 吡唑并吡啶激酶抑制剂
CN108658937A (zh) 一种双环生物碱类化合物及其制备方法和应用
CN103003273A (zh) 吡唑并吡啶激酶抑制剂
CN118339149A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
TWI607995B (zh) 氮雜環衍生物及其在藥物中的應用
CN117510500A (zh) 一种asperazepanones类生物碱制备方法与作为抗炎药物的应用
HK1207065B (en) Nitrogenous heterocyclic derivatives and their application in drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170731

R150 Certificate of patent or registration of utility model

Ref document number: 6186434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250